Colorectal cancer (CRC) is a cancer of the digestive tract that arises in the colon or rectum. Today, the treatment of CRC is guided by a patient’s molecular profile, particularly alterations in KRAS/NRAS, BRAF, HER2, dMMR/MSI-H, and NTRK. However, overall, the treatment algorithm is dominated by chemotherapies alone or in combination with EGFR- or VEGFR-targeted therapies. Current development consists of immunotherapy combinations for the larger MSS CRC population and further targeted development for the biomarkers listed above.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in colorectal cancer to help guide strategic and tactical commercial development decisions for market participants.